Real world evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)

Trial Identifier:	D3250R00101
Sponsor:	AstraZeneca
NCTID::	NCT05271526
Start Date:	May 2022
Primary Completion Date:	November 2023
Study Completion Date:	November 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russia	Moscow, Russia, 105077

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.